Article Details
Retrieved on: 2021-04-04 12:11:15
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Halozyme Therapeutics has a cash-to-debt ratio of 0.93, which which ranks worse than 83% of the companies in Biotechnology industry. The overall ...
Article found on: www.gurufocus.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here